HEPATIC MALIGNANCIES - IMPROVED TREATMENT WITH INTRAARTERIAL Y-90
HEPATIC MALIGNANCIES - IMPROVED TREATMENT WITH INTRAARTERIAL Y-90
复制标题
DOI：
10.1148/radiology.169.2.3174978
复制
发表时间：
1988-11-01
期刊：
影响因子：
19.7
通讯作者：
BRET, PM
中科院分区：
文献类型：
--
作者：
HERBA, MJ;ILLESCAS, FF;BRET, PM
对钇-90玻璃微球基质掺入治疗肝脏恶性肿瘤的改良方法进行了前瞻性评价。15例患者中有12例转移性结直肠癌、1例类癌、1例胰岛细胞瘤和1例肝癌，接受了3种剂量水平的治疗：10例患者，5，000 cGy（5，000 rad）; 3例患者，7，500 cGy（7，500 rad）; 2例患者，10，000 cGy（10，000 rad）。平均随访7个月（范围：2-12个月）。在10例患者中观察到肝脏疾病稳定，其中4例同时发生肝外疾病进展，导致2例死亡。另外两例死亡与恶性过程没有直接关系。在5名患者中发现肝脏疾病进展，其中3名患者在7-8个月时死亡。未发生手术、血液学或肺部并发症。3例有慢性酒精滥用史的患者在6-8周时发生晚期胃十二指肠溃疡。这种治疗方法似乎是可行和有效的。高剂量或有胃十二指肠溃疡病史或易患胃十二指肠溃疡的患者需谨慎。
An improved treatment method for hepatic malignancies with yttrium-90 incorporated into the matrix of glass microspheres was evaluated prospectively. Fifteen patients with 12 metastatic colorectal cancers, one carcinoid, one islet cell tumor, and one hepatoma were treated with three dose levels: 5,000 cGy (5,000 rad), ten patients; 7,500 cGy (7,500 rad), three patients; and 10,000 cGy (10,000 rad), two patients. Mean follow-up was 7 months (range, 2-12 months). Stable disease in the liver was seen in ten patients, four of whom had concurrent progression of extrahepatic disease, which resulted in two deaths. Two additional deaths were not directly related to the malignant process. Progression of liver disease was found in five patients, with three deaths occurring at 7-8 months. No procedural, hematologic, or pulmonary complications occurred. Late gastroduodenal ulceration occurred at 6-8 weeks in three patients who had histories of chronic alcohol abuse. This method of therapy seems to be feasible and efficient. Caution is necessary with high doses or with patients with a history of or predisposition to gastroduodenal ulcers.